Table 1 Patient characteristics
Number of patients (n) | 18 |
Age (years) median (range) | 58 (43–72) |
Sites of metastases | |
One site | 9 |
Two sites | 8 |
Three sites | 1 |
Tumour grade (n) | |
Well differentiated | 1 |
Moderately differentiated | 5 |
Poorly or undifferentiated | 12 |
Performance status according to Karnofsky (%) | |
70 | 1 |
80 | 8 |
90 | 4 |
100 | 4 |
NE | 1 |
Time (months) elapsing from last platinum dose to start of oral etoposide | |
Median (range) | 10 (1–24) |
Previous chemotherapy as first-line therapy (no. of patients) | |
Platinum based | 18 |
Cyclophosphamide | 9 |
Epidoxorubicin | 1 |
Paclitaxel | 5 |
Response to previous platinum (no. of patients) | |
Platinum sensitive | 9 |
Platinum resistant | 9 |
